LAUSR

Together with the increase in life expectancy of HIVinfected individuals with antiretroviral therapy (ART), morbidity and mortality from liver disease has sharply increased in individuals coinfected with hepatitis C or B and exhibit advanced liver fibrosis and cirrhosis [1,2]. Since 2009, hepatocellular carcinoma (HCC) has emerged as a more common feature of end-stage liver disease in this population [3] and a recent retrospective multicohort analysis reported an increase in HCC by 11% per calendar year between 2001 and 2014, with an incidence of 1.6 [95% confidence interval (CI)1⁄4 1.3– 2.0] cases per 1000 person-years of follow-up [4].